 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Inovio Pharmaceuticals, Inc. (INO) is a clinical stage biopharmaceutical company.
The firm develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.
The company's partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program.
Shares jumped yesterday after the company disclosed that its PENNVAX-GP, produced amongst the highest overall levels of immune response rates ever demonstrated in a human study by an HIV vaccine. Overall, 71 of 76 evaluable vaccinated participants showed a CD4+ or CD8+ cellular immune response to at least one of the vaccine antigens. Similarly, 62 of 66 evaluated participants demonstrated an env specific antibody response. None of the placebo recipients demonstrated either a cellular or an antibody response in the study. Higher share prices are expected for this stock.
52-Weeks Trading Range: $5.83 - $11.62
Entry Point: $8.60
Stop Loss: $8.25
Target Price: $9.57
INO closed at $8.00
